ChemDiv’s Antifungal Library contains 16,824 compounds.
Invasive fungal infections represent a continuous and serious threat to human health and they are associated with at least 1.5 million deaths worldwide each year. Such infections are prevalent in immunocompromised patients as a result of aggressive therapies and immunosuppressive infections such as HIV/AIDS. About 90% of these deaths are caused by species belonging to genera of fungi Candida, Aspergillus, Cryptococcus, Pneumocystis, Mucor and Rhizopus. In comparison with the development of new antibacterial drugs, antifungal drug development is more challenging because fungi are eukaryotes and many potential targets for therapy are also found in humans with substantial host toxicity risk.
Based on their targets for antifungal therapy antifungal agents can be classified in the following groups: inhibitors of ergosterol biosynthesis, fungal membrane disruptors, fungal cell wall synthesis, sphingolipids biosynthesis, nucleic acid synthesis, protein biosynthesis, microtubules biosynthesis inhibitors. 
 S. Campoy and J. L. Adrio, “Antifungals,” Biochem. Pharmacol., vol. 133, pp. 86–96, doi: 10.1016/j.bcp.11.019.